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There has been considerable interest in the neuropsy-
chological complications of HIV/AIDS in the last two 
decades.1,2 A range of HIV-related cognitive complica-
tions has been reported to include poor performance on 
tests of attention and concentration, movement and co-
ordination, reaction time and mental flexibility.1,3,4 These 
HIV-associated neurocognitive deficits (HAND) manifest 
in their mild form as minor cognitive motor disorder 
(MCMD) and grossly as HIV-associated dementia (HAD). 
The annual incidence of HAD is 7% after development of 
AIDS5 and it occurs in 20% of all HIV-infected persons,6 
although prevalence rates in sub-Saharan Africa are 
higher, ranging between 16% and 54%.7-9 With an HIV 
prevalence of 5.8% among adults there are more than 3 
million people living with HIV/AIDS (PLWHA) in Nigeria, 
more than in any other country in the world with the 
exception of South Africa and India.10-12 
HIV-associated cognitive impairment may be a factor 
contributing to poor medication adherence in sub-Saha-
ran Africa. With the increasing burden of disease there 
is clearly a need for a simple tool for rapid screening 
of cognitive functioning in HIV-infected persons. Efforts 
to develop appropriate screening techniques include the 
HIV Dementia Scale (HDS),13 a brief measure that has 
shown promise but lacks extensive independent evalua-
tion. The HDS (especially the modified and international 
versions, which exclude a difficult-to-administer anti-
saccadic task) has been shown to be simpler to admin-
ister than most cognitive tests used in HIV patients and 
may be useful for screening of cognitive dysfunction in 
clinics with no neurologist or neuropsychologist on the 
staff, as it does not require special training.13,14 This at-
tribute makes it appealing in the African setting, where 
it is likely to be applied by primary care providers be-
cause of the dearth of neuropsychologists in health care 
facilities. The present study examines the usefulness of 
the modified HDS in screening for cognitive deficits in a 
sample of HIV-positive adults in Nigeria. Dementia was 
diagnosed according to the universally accepted criteria 
in the Diagnostic and Statistical Manual for Mental Dis-
eases, 4th edition (DSM-IV-TR).15 
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objective. Information on the cognitive complications of HIV/AIDS from sub-Saharan Africa, where statistics on 
HIV are alarming, is sparse because of lack of validated cognitive tools. This study assessed the usefulness and 
predictive validity of the HIV Dementia Scale (HDS) as a screening tool in HIV-positive Nigerians.
Design. HIV-positive patients were randomly selected over a period of 2 months.
Setting. The HIV/AIDS outpatient clinic at the University of Benin Teaching Hospital, Benin City, Nigeria.
Subjects. Asymptomatic and symptomatic HIV-positive patients were compared with controls matched with 
regard to age, gender and level of education.
outcome measures. Cognitive performances on the modified HDS.
results. Performances on the HDS of 160 HIV-positive subjects (80 asymptomatic and 80 symptomatic) were 
compared with those of 80 HIV-negative controls. The mean HDS scores (maximum 12) were 10.78 (significant 
deviation (SD) 1.18) (HIV-negative subjects), 8.85 (SD 1.38) (HIV, asymptomatic) and 5.2 (SD 1.13) (HIV, symp-
tomatic); p<0.01. The HDS was found to have sensitivity of 97.3%, specificity of 80.4%, accuracy of 91.9% and 
a positive predictive value of 91.4% and a negative predictive value of 93.2%.
conclusion. The HDS was shown to be a sensitive screening tool for patients with HIV/AIDS in sub-Saharan 
Africa, but it was insensitive to memory impairment in asymptomatic HIV-positive patients.
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A total of 160 antiretroviral therapy-naïve subjects with 
positive enzyme-linked immunosorbent assays for HIV 
were randomly selected (using a table of random num-
bers) from the HIV/AIDS clinic at the University of Benin 
Teaching Hospital, Benin City, Nigeria, between May and 
June 2006. Demographic data were obtained and the 
HDS was used to assess the patients’ cognitive status 
after a detailed physical examination, including a com-
prehensive neuropsychiatric evaluation. The HIV-posi-
tive subjects were compared with 80 healthy seronega-
tive subjects selected randomly from hospital staff and 
undergraduate students. Informed consent was obtained 
from the patients and the controls. The patients and the 
controls were matched with regard to age, gender and 
level of education. 
The HIV-positive patients were categorised into two 
groups, asymptomatic and symptomatic, on the basis 
of their CD4+ T-lymphocyte counts (< 200 cells/μl for 
symptomatic) and the presence of HIV/AIDS-defining 
symptoms (unexplained fever – core body temperature 
>37.2oC – for more than 4 weeks, diarrhoea for more 
than 4 weeks, unexplained weight loss of >10% of pre-
vious body weight, and a generalised papular rash). We 
did not determine HIV clades (i.e. genetic subtypes of 
HIV groups) owing to lack of facilities, but some earlier 
studies have shown that the pattern of cognitive impair-
ments may be affected by different clades in sub-Saha-
ran Africa.16,17 
Clinical neuropsychological evaluation including the 
identification of diagnostic features of dementia based 
on the DSM-IV-TR was conducted on all patients by a 
single neurologist (OAO) who was blind to the HDS rat-
ing. Deterioration in daily functioning was determined 
from information provided by family members living 
with the patients. They were questioned on the presence 
of the following cognitive symptoms: (i) memory distur-
bances (forgetfulness of new events, difficulty finding 
words or not knowing common facts) affecting daily ac-
tivities; (ii) inability to cope with employment, academic 
demands and social activities that the patient could cope 
with before the onset of the illness; and (iii) deteriora-
tion in day-to-day functioning (i.e. difficulty in driving, 
shopping, handling money and self-care). Patients with-
out functional deterioration, i.e. cognitive disturbances 
sufficient to interfere with day-to-day functioning, were 
not considered to have dementia. 
Exclusion criteria included age under 18 years, already 
being on antiretroviral therapy, co-morbidity (diabetes 
mellitus, hypertension, epilepsy, hepatitis, intracranial 
disorders such as brain tumour, and other metabolic 
diseases), an inconclusive diagnosis, a major axis I 
psychiatric illness, a history of substance abuse, pres-
ence of clinical signs of cardiac failure, alcohol intake 
above 120 g per week or 13 units per week, a history 
of previous head injury with loss of consciousness, and 
anticholinergic medications.
MeaSUreS
The HDS was developed as a rapid screening test to 
assess for HAD.13 It is a paper-and-pencil neuropsy-
chological instrument with objective subtests meas-
uring psychomotor processing speed, verbal memory, 
constructional ability and executive function (response 
inhibition, set shifting) (Fig. 1). The score is based on 
performance for each subtest. This scale also exists in 
a modified form (eliminating the anti-saccadic subtest, 
which is often difficult to administer), and both the 
earlier and the modified versions have been validated 
for determining the presence and severity of HAD.12 The 
modified version was used in this study.
The modified scale has a maximum score of 12, i.e. 
psychomotor speed score of 6, verbal memory recall 
score of 4, and construction task score of 2. Details 
are outlined in Fig. 1. For the psychomotor speed and 
construction task, the subject is timed using a stop-
watch and the appropriate score given as indicated in 
Fig. 1. The modified HDS was administered by one of 
the authors (EE), who had no prior knowledge of the 
functional status categorisation using the DSM-IV-TR. 
StatiStical analYSeS
Statistical analysis was done using Epi Info 2000 soft-
ware (Centers for Diseases Control and Prevention, At-
lanta, Ga). The age, gender and level of education of 
the three groups were analysed for significant differ-
ences using the chi-square test. The means of the per-
formances of the HIV-positive patients were compared 
with those of the controls using the two-way analysis 
of variance. An F-test was used to determine the trend 
of linearity between cognitive performances and CD4+ 
levels. The level of significance was p<0.05. A receiver 
operating curve (ROC) was used to determine the cut-
off score for HDS. The strength of association between 
cognitive disturbance and HIV seropositivity was de-
termined with Mantel-Haenszel matched analysis and 
expressed as a likelihood ratio with 95% confidence 
interval (CI). The predictive value model using the 2×2 
contingency table yielded the sensitivity, specificity 
and predictive values. 
The demographic data for the subjects are set out in Ta-
ble I. The majority were in the 21 - 40-year age range. 
Clinical characteristics of the HIV-positive symptomat-
ic subjects are set out in Table II. Mean (SD) CD4+ T-
lymphocyte counts for the controls, the asymptomatic 
HIV-positive patients and the symptomatic HIV-posi-
tive patients were 668 (SD 8.6), 286 (SD 7.4) and 102 
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HDS scores (maximum 12) for the controls, asympto-
matic HIV-positive patients and symptomatic HIV-se-
ropositive patients were 10.78 (SD 1.18), 8.85 (SD 1.38) 
and 5.2 (SD 1.13), respectively (F=522.28, p<0.001). 
Details of the performances for the three categories 
are set out in Table III. There was a significant differ-
ence between the total scores for the normal subjects 
and the HIV-positive patients, irrespective of whether 
the patients were symptomatic or not. The asympto-
matic HIV-positive patients performed better than the 
symptomatic patients (t=20.13, p<0.001). Compari-
son of the memory scores did not reveal a significant 
difference between the performances of the controls 
and the asymptomatic HIV-positive patients, but the 
performance of the symptomatic HIV-positive patients 
was significantly poorer (p<0.05). 
The psychomotor speed of the HIV-positive subjects 
was significantly prolonged compared with the con-
trols (p<0.001) but the time taken to perform the con-
struction task did not differ significantly between the 
controls and the asymptomatic seropositive patients 
(p>0.05), although the construction task was per-
formed poorly by the asymptomatic HIV-positive group 
(Table III). Deterioration in the performance of the HIV-
seropositive subjects as CD4+ T-lymphocyte counts 
decreased was observed. The F-test for linear trend 
showed this observation to be significant (p<0.05), as 
outlined in Table IV.
A cut-off score of 9, obtained by ROC analysis, was used 
to determine the sensitivity, specificity and predictive 
values of the HDS. The HDS total scores were below 
the cut-off score of 9 in 109 HIV-seropositive patients 
(68.1%), but 41 (25.6%) of the patients had no features 
of functional deterioration and their HDS total scores 
were above 9. The total HDS scores were normal (i.e. 
above the cut-off score of 9) in 10 patients with func-
tional deterioration, while 4 patients had no functional 
deterioration but had abnormal total HDS scores (Table 
V). This implies false-positive and false-negative rates 
of 8.6% and 6.8%, respectively. The likelihood ratio for 
cognitive disturbance in HIV-positive patients based on 
modified HDS scores in the presence of functional de-
terioration was 41 (95% CI 13 - 138). This implies that 
patients with clinical evidence of dementia based on 
cognitive symptoms sufficient to interfere with func-
tional abilities are approximately 40 times more likely to 
have a score of <9 on the modified HDS. The sensitivity 
of the modified HDS was 97%, the specificity was 80%, 
the positive predictive value was 91% and the negative 
predictive value was 93% (overall accuracy, 92%).
0





Give 4 words to recall and 1 second to say each. Then ask the
patient all 4 after you have said them.
6 Psychomotor speed
Ask patient to write the alphabet in uppercase letters
horizontally across the page (use back of questionnaire) and
record time …… seconds.
≤21sec = 6; 21.1 – 24 sec = 5; 24.1 – 27 sec = 4; 27.1 – 30
sec = 3; 30.1 – 33 sec = 2; 33.1 - 36 = 1; >36 sec = 0
4 Memory – Recall
Ask for the 4 words from Memory – Registration test above.
Give 1 point for each correct word. For words not recalled,
prompt with a semantic clue. Give half a point for each
correct word after prompting.
2 Construction
Copy the cube below; record time …… seconds
<25 sec = 2; 25 – 35 sec = 1; >35 sec = 0
Fig. 1. Modified HIV Dementia Scale.
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The epidemiology of HIV-associated cognitive impair-
ment in Africa is poorly understood. Vaguely defined 
criteria for cognitive impairment and assessment tools 
that are inadequate and lack validation, coupled with 
absence of normative population data, have limited 
proper study of cognitive impairment in HIV-positive 
populations in these settings. Although the clinical 
presentation of dementia may vary, depending on the 
causation, the diagnostic features are constant as set 
out in the DSM-IV-TR. The performance of an individ-
ual in the cognitive subtests may therefore reflect the 
degree of interference with performing similar tasks 
in daily life, although this is not invariable, as a poor 
cognitive score does not always infer functional inca-
pacity. By comparing the performances of HIV-positive 
patients with controls, we assessed the differences in 
their abilities in these cognitive domains. 
This study showed the usefulness and predictive valid-
ity of the modified HDS as a screening cognitive tool in 
Nigerian patients. The findings applied to subjects who 
met the DSM-IV diagnostic criteria for dementia and 
were also reported by family members to display func-
tional deterioration in performance of daily activities. 
The modified HDS revealed deficits in all the tested 
cognitive domains in the symptomatic HIV-positive pa-
tients. Although the modified HDS showed impairment 
in cognitive abilities of the asymptomatic HIV-positive 
patients compared with the controls, the memory per-
formances were similar. The predictive values, sensitiv-
ity and specificity values obtained from this study are 
comparable to those obtained by earlier authors, who 
used cut-off scores of 9 and 7.5.18,19 The memory scores 
and the time taken to perform the construction task did 
not differ significantly between controls and asympto-
matic HIV-positive patients. A similar observation was 
reported by Smith et al.20 These findings corroborate 
earlier reports of a low prevalence of memory impair-
ment among asymptomatic HIV-positive patients.4,21,22 
The total scores showed the ability of the modified 
HDS to demonstrate the presence of cognitive impair-
ments in HIV/AIDS, and it is therefore likely to be es-
pecially useful for population-based studies. It clearly 
demonstrated the presence of psychomotor retardation 
in the HIV-positive subjects, as has been reported by 
others.1,5,14 The 68.1% prevalence of HAD observed in 
this study using the modified HDS is high. This figure 
DiScUSSion
  controls (n=80) asymptomatic HiV positive (n=80) Symptomatic HiV positive (n=80)
Gender 
   Male         32                       32                     34
   Female         48                       48                     46
   χ2          0.104
   p           0.95
Age groups (yrs)
   <20          6                       4                     6
   21 - 30         25                       26                     26 
   31 - 40          27                       28                     26
   41 - 50         14                       14                     15
   >50          8                       8                     7
   χ2          0.734
   p          0.99
Age range (yrs)         8 - 58                       20 - 64                     18 - 56
Level of education 
   Primary          18                       19                     18
   Secondary          37                       38                     38
   Tertiary          25                       23                     24
   χ2          0.137
   p          0.99 
Primary education = maximum of 6 years of schooling; secondary education = more than 6 years of schooling without post-secondary education; tertiary education = more than 11 years of 
schooling with post-secondary education.
taBle i. DeMograPHic Data oF tHe StUDY SUBJectS
Symptom Frequency (n) % 
Unexplained fever (>37.2oC for >4 wks)          72 90
Unexplained weight loss (>10% of previous body weight)          76 95
Persistent diarrhoea (>4 wks)          62 78 
Generalised papular rash          48 60
Generalised herpes zoster          18 23 
Clinical/radiological signs of pulmonary tuberculosis          54 68
Unexplained anaemia (haematocrit <30% or haemoglobin<9 g/dl)           68 85
taBle ii. clinical cHaracteriSticS oF tHe SYMPtoMatic HiV-PoSitiVe SUBJectS
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is higher than rates of 16 - 54% reported by other au-
thors in Africa7-9 but similar to the 64.3% prevalence 
of cognitive impairment in a Nigerian population with 
asymptomatic mild HIV infection.23 This may be due to 
HIV clade diversity and the differences in the sensitiv-
ity of neurocognitive assessment tools utilised in these 
studies. More recently studies have demonstrated the 
presence and pattern of cognitive impairments in black 
Africans with HIV/AIDS, but most of these studies used 
either complex psychometric21,24 or computerised cog-
nitive tests,22,25 which are difficult to administer in 
most rural clinical settings and cumbersome for com-
munity-based research in sub-Saharan Africa. 
The prevalence data available for HIV-associated cog-
nitive impairment in Africa represent rates in people 
presenting to tertiary care centres and are unlikely 
to reflect rates in the general population. The level of 
education of research subjects affects performance on 
the HDS (a higher level of education improving cogni-
tive performance), but the effects of age and gender 
remain inconclusive.3,19 The HDS has been validated in 
subcortical cognitive impairment, the pattern of im-
pairment observed in HIV-associated neurocognitive 
deficits.19 The modified HDS requires no computer. It 
is a pen-and-paper cognitive instrument that can eas-
ily be administered in rural clinic settings. It can be 
 controls  asymptomatic HiV positive Symptomatic HiV positive 
Memory (mean SD)) 3.68 (0.15)             3.56 (0.64)             1.82 (1.84)
              (p>0.05)*             (p<0.001)†
Construction (mean (SD)) 1.96 (0.20)             1.23 (0.62)             0.84 (0.71)
              (p<0.05)             (p<0.001
Time taken for task 9.84 (5.84)             10.12 (3.46)             24.21 (6.43)
(s) (mean (SD)) (range) (2 - 28)             (4 - 32)             (16 - 56)
              (p>0.05)             (p<0.001)
Psychomotor speed (mean (SD)) 5.14 (0.77)             4.06 (1.72)             2.54 (1.46)
              (p<0.01)             (p<0.001)
Time taken for task 15.9 (4.59)             19.32 (6.72)             39.2 (2.44)
(s) (mean (SD)) (range) (10 - 36)             (11 - 48)             (26 - 54)
              (p<0.001)             (p<0.001)
Total score 10.78 (1.18)             8.85 (1.38)             5.2 (1.13)
              (p<0.001)             (p<0.001)
*Levels of significance for comparison between mean performances of the controls and asymptomatic HIV-positive subjects. 
†
Levels of significance for comparison between mean performances of the controls and symptomatic HIV-positive subjects.
taBle iii. HiV DeMentia Scale ScoreS For tHe SUBJectS
cognitive domains Slope (r2) F-values  p-values 
Memory -0.98 (0.33) 120.75 p<0.0001
Construction -0.41 (0.26) 86.90 p<0.0001
Time taken 7.19 (0.47) 283.45 p <0.001
Psychomotor speed -1.15 (0.31) 111.70 p<0.001
Time taken 9.15 (0.64) 556.76 p<0.001
   Total  -3.62 (0.65) 579.11 p<0.001
taBle iV. tHe coMPariSon oF cognitiVe PerForMance WitH cD4+ leVelS USing tHe F-teSt For linear trenD
 Symptomatic HiV+  asymptomatic HiV+ HiV+ subjects  controls HiV-  
 (N=80) (N=160) (N=80) (N=80)
Functional status*
(N (%)) 
   Deterioration  80 (100.0) 39 (48.75) 119 (74.38) NA
   Still coping 0 (0) 41 (51.25) 41 (25.62) NA
HDS total score  
(mean (SD)) 5.2 (1.13) 8.85 (1.38) 7.03 (1.64) 10.78 (1.18)
(maximum 12) 
   Normal (N (%))   4 (5.0) 47 (58.75) 51 (31.87) 78 (97.5)
   Abnormal† (N (%)) 76 (95.0) 33 (41.25) 109 (68.13) 2 (2.5)
χ2 84.94 p<0.001‡
*Based on deterioration of functional abilities of patients (as expressed by family members living with patients).
†
HDS cut-off score obtained by receiver operating characteristics analysis (cut-off score of 9; abnormal score <9).
‡
Mantel-Haenszel matched analysis. 
NA = not applicable.
taBle V. FUnctional anD cognitiVe StatUS oF SUBJectS anD HDS ScoreS
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administered by health care providers who are non-
professionals but have received instruction in its ap-
plication. It is therefore suitable for community-based 
research in low-income developing countries. It has 
acceptable false-negative and false-positive rates. On 
the basis of our findings we believe it to be a useful 
screening tool for determining the baseline cognitive 
abilities of patients with HIV/AIDS and recommend its 
use for monitoring the response of patients with HIV-
associated cognitive impairment who are on highly ac-
tive antiretroviral therapy (HAART), as an earlier study 
has demonstrated improvement in neurocognitive and 
functional performance in HIV-positive individuals on 
HAART in sub-Saharan Africa.26
In conclusion, this study suggests the usefulness of the 
HDS as a screening tool for the assessment of cogni-
tive abilities of patients with HIV/AIDS in sub-Saharan 
Africa. The sensitivity, specificity and predictive values 
compared favourably with those obtained among pa-
tients in developed countries. It is, however, limited by 
its inability to detect significant memory impairment in 
asymptomatic HIV-seropositive patients.
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